The handle http://hdl.handle.net/1887/20522 holds various files of this Leiden University dissertation.

Author: Stevanović, Sanja
Title: Exploiting HLA-class II disparity for anti-tumor immunity by allogeneic cellular immunotherapy
Issue Date: 2013-02-12
REFERENCES

CHAPTER 1 AND 6: INTRODUCTION AND GENERAL DISCUSSION


75. Cignetti A, Bryant E, Allione B et al. CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood 1999;94:2048-2055.


135. Xun CQ, Tsuchida M, Thompson JS. Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H2 incompatible transplantation. Transplantation 1997;64:297-302.


159. **Shaw BE, Marsh SG, Mayor NP, Russell NH, Madrigal JA.** HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. Blood 2006;107:1220-1226.


207. Pearce DJ, Taussig D, Zibara K et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 2006;107:1166-1173.


240. Rutten CE, van Luxemburg-Heijs SAP, van der Meijden ED et al. HLA-DPB1 mismatching results in the generation of a full repertoire of HLA-DPB1 specific CD4+ T-cell responses showing immunogenicity of all HLA-DPB1 alleles. Biol.Blood Marrow Transplant. 2010


254. Kremer AN, van der Meijden ED, Honders MW et al. Endogenous HLA-class-II epitopes that are immunogenic in vivo show distinct behavior towards HLA-DM and its natural inhibitor HLA-DO. Blood 2012

CHAPTER 2


CHAPTER 3


47. **Piguet PF, Grau GE, Allet B, Vassalli P.** Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J.Exp.Med. 1987;166:1280-1289.

CHAPTER 4


CHAPTER 5


28. Rutten CE, van Luxemburg-Heijs SA, van der Meijden ED et al. HLA-DPB1 mismatching results in the generation of a full repertoire of HLA-DPB1 specific CD4+ T-cell responses showing immunogenicity of all HLA-DPB1 alleles. Biol.Blood Marrow Transplant. 2010


44. **Stevanovic S, Griffioen M, Nijmeijer BA et al.** Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia. Leukemia 2012;26:312-322.


**SUPPLEMENTARY METHODS**

